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Summary
 
We have previously observed that HIV-1 replication is suppressed in uninflamed lung and in-
creased during tuberculosis. In vitro THP-1 cell–derived macrophages inhibited HIV-1 repli-
cation after infection with 
 
Mycobacterium tuberculosis.
 
 Suppression of HIV-1 replication was asso-
ciated with inhibition of the HIV-1 long terminal repeat (LTR) and induction of ISGF-3, a
type I interferon (IFN)–specific transcription factor. Repression of the HIV-1 LTR required
intact CCAAT/enhancer binding protein (C/EBP) sites. THP-1 cell–derived macrophages
infected with 
 
M. tuberculosis
 
, lipopolysaccharide, or IFN-
 
b
 
 induced the 16-kD inhibitory
C/EBP
 
b
 
 isoform and coincidentally repressed HIV-1 LTR transcription. C/EBP
 
b
 
 was the
predominant C/EBP family member produced in THP-1 macrophages during HIV-1 LTR
repression. In vivo, alveolar macrophages from uninflamed lung strongly expressed inhibitory
16-kD C/EBP
 
b
 
, but pulmonary tuberculosis abolished inhibitory C/EBP
 
b
 
 expression and in-
duced a novel C/EBP DNA binding protein. Therefore, in vitro, proinflammatory stimulation
produces an IFN response inhibiting viral replication by induction of a C/EBP
 
b
 
 transcriptional
repressor. THP-1 cell–derived macrophages stimulated with type I IFN are similar to alveolar
macrophages in the uninflamed lung in vivo. In contrast, the cellular immune response in
active pulmonary tuberculosis disrupts this innate immunity, switching C/EBP expression and
allowing high level viral replication.
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A
 
IDS patients without pneumonia have very low levels
of HIV-1 provirus or viral particles in the lung. Only
1 in 10
 
5
 
 alveolar macrophages is infected (1), and AIDS pa-
tients with clear chest x rays have no detectable virus in
bronchoalveolar lavage (BAL)
 
1
 
 fluid (2). The situation is
remarkably different in patients with pulmonary infiltrates:
the number of lung cells infected and the level of virus pro-
duced are increased up to 1,000-fold (2–5). The alveolar
macrophage is an important source of HIV-1 production in
patients with tuberculosis (6). The high levels of virus pro-
duced during infections such as tuberculosis and the in-
creased viral mutation produced by enhanced viral replica-
tion (2) may contribute to the accelerated course of AIDS
after opportunistic infection (7).
Inflammatory stimuli such as TNF-
 
a
 
 and LPS suppress
viral replication in macrophages (8–12). The negative regu-
latory element (NRE) is the DNA element responsible for
suppressing the HIV-1 LTR after LPS stimulation (8). The
transcription repressors induced by LPS stimulation of mac-
rophages have not been identified. The suppression of
 
1
 
Abbreviations used in this paper:
 
 BAL, bronchoalveolar lavage; CAT,
chloramphenicol acetyltransferase; C/EBP, CCAAT/enhancer binding
protein; EMSA, electromobility shift assay; IRF-1, IFN regulatory factor
1; ISGF-3, IFN-stimulated gene factor 3; ISRE, IFN-stimulated response
element(s); LAP, liver-activating protein; LIP, liver-enriched inhibitory
protein; moi, multiplicity of infection; NF, nuclear factor; NRE, negative
regulatory element; Stat, signal transducer and activator of transcription.
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HIV-1 replication seen after LPS stimulation closely resem-
bles the suppression seen after addition of IFNs (9). Type I
IFN is required for the suppressive effects of LPS and
TNF-
 
a
 
 on viral replication (11, 12). Macrophages derived
from knockout mice deficient in the IFN receptor 
 
a
 
/
 
b
 
p100, also known as IFNR-1, do not repress viral replica-
tion after stimulation with LPS or TNF-
 
a
 
 (12, 13). In
macrophages with intact type I IFN receptors, antibodies to
IFN-
 
b
 
 but not IFN-
 
a
 
 will block the suppressive effects of
proinflammatory stimuli (11). IFN-
 
b
 
 is also the most po-
tent inhibitor of HIV-1 replication in macrophages, pro-
ducing a 99% inhibition of p24 production after treatment
with 1 U/ml (9).
IFN-
 
a
 
 and IFN-
 
b
 
 are the major type I IFNs, which
constitute an essential early arm of the innate immune re-
sponse (14). Type I IFNs are expressed at low levels in nor-
mal tissue macrophages (15). Knockout mice deficient in
type I IFN receptors have reduced levels of IFN responsive
enzymes in macrophages compared with normal mice, sup-
porting the concept that macrophages are primed by low
levels of type I IFN in the absence of viral infection (13).
Signal transduction in the type I IFN system is mediated by
a high-affinity transmembrane receptor composed of two
subunits (16). Knockout mice deficient in the p100 subunit
are particularly susceptible to viral infection (13, 17). Upon
binding of type I IFNs to their receptor, specific protein ty-
rosine kinases are activated, and signal transducer and acti-
vator of transcription (Stat) proteins are phosphorylated.
IFN-stimulated gene factor 3 (ISGF-3) is then rapidly as-
sembled without the need for protein synthesis. ISGF-3 is a
heterotrimer of Stat-1, Stat-2, and p48 that rapidly translo-
cates to the nucleus, binds promoter sequences named
IFN-stimulated response elements (ISRE), and activates
gene expression (18).
The HIV-1 LTR NRE has three CCAAT/enhancer
binding protein (C/EBP) sites that bind C/EBP
 
b
 
 (19). The
C/EBP
 
b
 
 gene has no introns, but two different proteins
are produced from the same mRNA. Large 30–37-kD iso-
forms stimulate transcription while small (
 
z
 
16–20-kD) iso-
forms repress transcription (20, 21). The small inhibitory
C/EBP
 
b
 
 is likely produced when the ribosome starts pro-
tein translation from an internal ribosome entry site in the
C/EBP
 
b
 
 mRNA. Calame and colleagues transfected con-
structs expressing inhibitory 16-kD C/EBP
 
b
 
 isoform and
demonstrated inhibition of HIV-1 replication and LTR
promoter function (22, 23). Further, intact C/EBP sites are
required for HIV-1 replication in macrophages but not
lymphocytes (24). C/EBP sites in the LTR of Rous sar-
coma virus can mediate either stimulation or repression of
promoter function depending on which C/EBP isoform is
expressed (25). These data suggest that transcription factors
binding to the C/EBP sites in the LTR are important en-
hancers and repressors of replication in monocytes. Cyto-
kine genes such as TNF-
 
a
 
 also have C/EBP binding sites,
and transfection of inhibitory C/EBP
 
b
 
 represses TNF-
 
a
 
promoter activity (26).
In this investigation, we demonstrate that 
 
Mycobacterium
tuberculosis
 
 infection of THP-1 macrophages suppresses
HIV-1 replication and induces a type I IFN response. This
is accompanied by repressed LTR transcription that depends
on intact C/EBP sites in the LTR. An inhibitory 16-kD
C/EBP
 
b
 
 transcription factor is induced by 
 
M. tuberculosis
 
 or
LPS, and C/EBP
 
b
 
 accounts for 
 
.
 
95% of the LTR NRE
binding. Treatment of macrophages with IFN-
 
b
 
 also represses
LTR transcription and induces the inhibitory C/EBP
 
b
 
.
Resting alveolar macrophages strongly express the inhibi-
tory C/EBP
 
b
 
 but downregulate it in pulmonary tubercu-
losis and switch expression to another C/EBP site binding
factor.
 
Materials and Methods
 
Study Population.
 
We evaluated seven patients with active
pulmonary tuberculosis with sputum or lung tissue culture posi-
tive for 
 
M. tuberculosis.
 
 Tuberculosis patients had received antimy-
cobacterial therapy for 1–7 d before fiberoptic bronchoscopy.
HIV-1 testing on all patients was done with ELISA and con-
firmed by Western blot; five out of seven were HIV-1 positive.
None were on antiretroviral therapy during the acute illness. All
patients had segmental infiltrates; radiographically uninvolved
lobes were identified, and a separate BAL was performed and
processed from this segment. Three out of the seven were smok-
ers; all seven were male. Their mean age 
 
6
 
 SD was 40 
 
6
 
 11 yr.
Two normal volunteers were lavaged; both were HIV-1 nega-
tive, and both had a normal chest radiograph and spirometry.
BAL was approved by the Human Subjects Review Committees
of New York University Medical Center and Bellevue Hospital
Center.
 
BAL Cells.
 
BAL was performed with a flexible fiberoptic
bronchoscope with local Xylocaine anesthesia. We instilled six
50-ml aliquots (total 300 ml) of normal saline and suctioned se-
quentially from radiographically uninvolved and involved seg-
ments. The lavage fluid was filtered through sterile gauze to re-
move mucous, and total cells were counted in a hemacytometer.
Cell differentials were performed on cytospin slides stained with
Wright-Giemsa. For purification of alveolar macrophages, BAL
cells were spun and resuspended in RPMI 1640 and allowed to
adhere to plastic plates for 3 h. Cells were recovered by gentle
scraping with a rubber policeman. Alveolar macrophages were
95% pure by morphology and nonspecific esterase staining.
 
HIV-1–Mycobacteria Coinfection.
 
THP-1 cells (10
 
4
 
 cells/well
in 96-well plates) were incubated overnight with 10 ng/ml PMA.
Cells were infected with HIV-1 strains BaL or NL4-3 (1 ng p24/
ml) and 
 
M. tuberculosis
 
 H37Ra at various multiplicities of infec-
tion (moi) for 2 h at 37
 
8
 
C. They were washed twice and incu-
bated with RPMI 1640/10% FCS containing PMA. p24 was as-
sayed by ELISA.
 
Stable LTR Reporter Constructs.
 
BF-24 cells, obtained from
the AIDS Reference Reagent Program (#1296; Rockville, MD),
are THP-1 cells with an integrated HIV-1 LTR.CAT construct.
pHIV-CAT LTR reporter construct was obtained from the
AIDS Reference Reagent Program (#2619). The HindIII-XhoI
LTR fragment was transferred to the HindIII-XhoI site of pGL 3
(Stratagene, Inc., La Jolla, CA). The SalI-NotI pGL 3 LTR lu-
ciferase fragment was then transferred to a modified pCR3 plas-
mid carrying a NotI site (Invitrogen Corp., Carlsbad, CA). Dou-
ble-stranded PCR mutagenesis was performed according to the
manufacturer’s instruction (Stratagene, Inc.). Three oligonucle-
otides and their reverse complements were used to mutate the C/
EBP domains 1, 2, and 3 of the HIV-1 LTR (see Fig. 3 for posi- 
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tion of C/EBP domains and mutations introduced). Mutants
were selected for addition of PstI or PvuII sites and were con-
firmed by complete sequencing of the LTR. 2 
 
3
 
 10
 
6
 
 THP-1 cells
were transfected with 2 
 
m
 
g of mutant or wild-type plasmid mixed
with 10 
 
m
 
l of lipofectamine (GIBCO BRL, Gaithersburg, MD)
for 5 h; transfected cells were cultured in RPMI/10% FCS at 10
 
5
 
cells/well in 24-well plates. After 24 h, 700 
 
m
 
g/ml of G418 was
added. Resistant clones were expanded and screened for lu-
ciferase production.
 
Cell Stimulation and Nuclear Protein Isolation.
 
Cells were incu-
bated with PMA at 20 ng/ml and live 
 
M. tuberculosis
 
 at an moi of
0.1–10 or PMA and LPS at 10 
 
m
 
g/ml. When used, IFN-
 
b
 
 was
added at 1 U/ml after pretreatment for 24 h with PMA at 20 ng/
ml. Cells were harvested at various time points and were washed
in PBS twice. Nuclei were isolated by NP-40 lysis and high salt
extraction as described (27). Whole cells were lysed and extracted
with RIPA (PBS, 1% NP-40, 0.5% deoxycholate) with 30 
 
m
 
l/ml
aprotinin and 1 mM sodium orthovanadate for 30 min, and dis-
rupted by passage through a 21 gauge needle; 1 mM PMSF was
then added. Protein extracts for chloramphenicol acetyltransferase
(CAT) ELISA or luciferase assays (both from Boehringer Mann-
heim) were made according to the manufacturer’s instructions.
Reporter activity was corrected for cell viability as measured by
trypan blue exclusion.
 
Immunoblots.
 
100 
 
m
 
g of protein was added to a 10–20% linear
gradient SDS-polyacrylamide gel. After electrophoresis, protein
was electrotransferred to a nylon membrane and probed with 3
 
m
 
g of polyclonal C/EBP
 
b
 
 antibody (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA) in 50 ml blotto and visualized with 1.2 
 
m
 
g
anti–rabbit horseradish peroxidase and ECL (Amersham Pharma-
cia Biotech, Piscataway, NJ). Blots were then reprobed with anti-
body to nuclear factor (NF)-
 
k
 
B p65 Rel (Santa Cruz Biotechnol-
ogy, Inc.).
 
Electromobility Shift Assay.
 
DNA probe was labeled with [
 
a
 
-
 
32
 
P]dCTP using Klenow DNA polymerase in a fill-in reaction.
The overlapping oligonucleotides used for wild-type NRE probe
were 
 
2
 
184 5
 
9
 
AGCAAACTAGC
 
ATTTCATC
 
3
 
9
 
-166 and 
 
2
 
160
5
 
9
 
CCATG
 
TGATGAAAT
 
GC3
 
9
 
-175, with bold letters denot-
ing the C/EBP binding domain. The mutant sequences were
 
2
 
184 5
 
9
 
AGCAAACTAGCA
 
GGGG
 
3
 
9
 
-163 and 
 
2
 
160 5
 
9
 
CCA-
TGT
 
CCCCTGCA
 
GC3
 
9
 
-175, with bold letters denoting muta-
tion from wild-type. Full-length 25-bp reaction products were
isolated on a 20% acrylamide gel, and 2 
 
3
 
 10
 
5
 
 cpm labeled DNA
was mixed with 10 
 
m
 
g of protein extract, 2.5 
 
m
 
g poly dI/dC,
and gel mobility shift buffer. The ISRE probe was 59CTC-
GGGAAAGGGAAACCGAAACTGAAGCC39, with the ISRE
homology in bold (28). The nonspecific competitor on the ISRE
electromobility shift assay (EMSA) was 59CTCTCTGCAAGG-
GTCATCAGTAC39. For supershift experiments, 1 mg of anti-
body was added to the reaction (C/EBP antibodies from Santa
Cruz Biotechnology, Inc.; Stat-1 and Stat-2 antibodies were a gift
from Chris Schindler). The DNA–protein complexes were elec-
trophoresed on a 6% polyacrylamide gel at 48C and analyzed by
autoradiography. Films of immunoblots and EMSA were scanned
with a Personal densitometer (Molecular Dynamics, Sunnyvale,
CA). Results are presented as the mean 6 SEM.
Results
M. tuberculosis Infection Suppresses HIV-1 Replication and
LTR Promoter Function in Macrophages. THP-1 cell–derived
macrophages support high levels of HIV-1 replication, pro-
ducing between 1 and 3 ng/ml of p24 antigen 7 d after in-
fection (Fig. 1, A, moi 0). M. tuberculosis suppressed HIV-1
replication in a dose-dependent manner. At an moi of 1,
there was at least a 50% reduction of HIV-1 p24 in both vi-
ral strains without reduced cell viability. At an moi of 10,
there was a 70–90% reduction in viral production. M. tu-
berculosis suppressed replication of HIV-1 BaL (macrophage
trophic) and HIV-1 NL4-3 (lymphocyte trophic). Similar
results were obtained from blood monocytes differentiated
with M-CSF and infected with Mycobacterium bovis (data
not shown).
To test if the reduction in viral replication was due to re-
duced LTR-driven transcription, these experiments were
repeated on BF-24 cells (THP-1 cells with a stable HIV-1
LTR reporter construct). M. tuberculosis suppressed HIV-1
LTR–driven CAT production in PMA-differentiated BF-
24 cells (Fig. 1 B). Similar to the decrease in HIV-1 p24,
CAT concentration declined by 33% at an moi of 1 and
66% at an moi of 10.
M. tuberculosis Infection of Macrophages Induces an IFN Re-
sponse. Since other proinflammatory stimuli such as LPS
inhibit viral replication by a type 1 interferon response (12),
we tested if M. tuberculosis infection also induced an inter-
feron response. We assayed cell extracts for activation of a
type I IFN specific transcription factor in cells infected with
M. tuberculosis. Extracts of differentiated THP-1 cells were
used in EMSA with an ISRE-containing DNA probe.
Stimulation of THP-1 macrophages with IFN-a or in-
fection with M. tuberculosis at an moi of 1 induced an
ISRE–protein complex that was not present in unstimu-
lated THP-1 macrophages (Fig. 2, lanes 1 and 2). Both
stimuli induced the same complex, although M. tuberculosis
produced less ISRE–protein complex than 500 U/ml of
IFN-a (Fig. 2, lane 3). The complex specifically bound
ISRE sequences and contained Stat-1 and Stat-2 but not
IFN regulatory factor 1 (IRF-1). Excess unlabeled ISRE
oligonucleotide disrupted the DNA–protein complex (Fig.
2, lanes 4–6), but excess nonspecific oligonucleotide did
not (Fig. 2, lanes 7–9). Antibodies against Stat-1 (Fig. 2,
lanes 10–12) and Stat-2 (Fig. 2, lanes 13–15) disrupted the
DNA–protein complex, whereas antibodies to IRF-1 did
not (Fig. 2, lanes 16–18). Therefore, the DNA–protein
complex induced by infection with M. tuberculosis had the
Figure 1. HIV-1 replication
and LTR function after infection
with M. tuberculosis. ( A ) HIV-1
replication is suppressed by M.
tuberculosis infection. Monocytic
THP-1 cells differentiated to
macrophages by PMA were in-
fected with HIV-1 BaL (d) or
HIV-1 NL4-3 (j). HIV-1 repli-
cation was measured by p24 pro-
duction at day 7 after infection.
(B) HIV-1 LTR is repressed by
M. tuberculosis infection. BF-24
cells containing a stable inte-
grated HIV-1 LTR CAT con-
struct were differentiated with PMA and infected with M. tuberculosis at
various moi. CAT activity was measured 48 h later.1258 Interferon Induces an Inhibitory C/EBP Transcription Factor
characteristics of ISGF-3, a type I IFN–specific transcrip-
tion factor.
C/EBP Sites Are Required for HIV-1 LTR Promoter
Repression in Macrophages. The NRE of the HIV-1 LTR
is required for repression of the HIV-1 LTR after stimula-
tion of macrophages with LPS (8), and the NRE contains
C/EBP transcription factor binding sites (19). To test if
C/EBP binding factors contributed to promoter repression
in macrophages after infection with M. tuberculosis, HIV-1
LTR reporter constructs carrying three C/EBP binding site
mutations were generated (Fig. 3). Wild-type and C/EBP
mutant LTR reporter constructs were stably transfected
into THP-1 cells. In time course experiments, M. tuberculo-
sis infection inhibited wild-type LTR reporter activity 38%
from 24 to 48 h after infection, and LPS stimulation inhib-
ited wild-type LTR reporter activity by 40% from 48 to 72 h
after stimulation (Fig. 4 A). HIV-1 LTR CAT and HIV-1
LTR luciferase produced similar results.
Mutation of the C/EBP sites in the HIV-1 LTR abol-
ished repression of LTR reporter activity in macrophages
after infection with M. tuberculosis or stimulation with LPS
(Fig. 4 B). Reporter activity increased 20% after infection
with M. tuberculosis and 40% after stimulation with LPS
when C/EBP sites were mutated. Consistent with previous
reports demonstrating the importance of C/EBP sites in
transcriptional activity of the LTR (22–24), the C/EBP
mutant had reduced total activity compared with the wild-
type HIV-1 LTR.
An Inhibitory 16-kD C/EBPb Isoform Is Induced by Proin-
flammatory Stimuli and IFN-b. Since C/EBP binding sites
are required for HIV-1 LTR–mediated transcription in
macrophages (22, 23) and the C/EBPb gene can produce a
16-kD dominant negative transcription factor (20, 21), we
investigated whether changes in C/EBPb expression could
account for repression of the HIV-1 LTR. Initial experi-
ments were conducted with M. tuberculosis infection and
repeated with LPS, another proinflammatory stimulus that
inhibits LTR reporter activity and HIV-1 replication in
macrophages (8, 9).
THP-1 cell–derived macrophages produced a 16-kD in-
hibitory C/EBPb in nuclear extracts 48–72 h after stimula-
tion with LPS (Fig. 5 A) or 24–48 h after infection with M.
tuberculosis (data not shown). A stimulatory 37-kD C/EBPb
was also induced over the same time course. The ratio of
inhibitory to stimulatory C/EBPb was 0.8 after 72 h of
LPS stimulation (Table 1). Inhibition predominates at
stoichiometric ratios .0.2 (20, 21). A cross-reacting 40-kD
protein was detected in the immunoblots. This band is
nonspecific since it is expressed in unstimulated THP-1
cells that have negligible C/EBP DNA binding activity.
IFN-b also induced the inhibitory 16-kD C/EBPb in
THP-1 macrophages (Fig. 5 B). In time course experi-
ments, induction of inhibitory C/EBPb started 3 h after
addition of IFN-b and achieved its maximum at 48 h. The
amount of inhibitory C/EBPb induced with IFN-b and
LPS were the same (Fig. 5 B, last two lanes), but induction
of the inhibitory transcription factor by IFN is more rapid
than with LPS stimulation, and the ratio of inhibitory to
stimulatory C/EBPb was 3.6 (Table 1). In dose–response
experiments, 1 U/ml of IFN-b maximally induced the 16-
kD C/EBPb (data not shown).
1 U/ml of IFN-b reduced HIV-1 LTR CAT expression
by 50% within 3 h in BF-24 cells differentiated with PMA
(Fig. 5 C). The reduction of LTR activity was coincident
Figure 2. ISGF-3 binding to ISRE DNA in THP-1 macrophages.
Treatment with IFN-a and infection with M. tuberculosis induces ISGF-3
expression. Lane 1, Unstimulated macrophages do not express ISGF-3.
Lane 2, Stimulation with IFN-a (IFN) induces an ISRE binding com-
plex. Lane 3, Infection with M. tuberculosis (Tb) produces a comigrating
complex (arrow). Lanes 4–6, The ISRE–protein complex was disrupted by
excess unlabeled ISRE-containing competitor. Lanes 7–9, The ISRE–
protein complex was not disrupted by excess unlabeled nonspecific oligo-
nucleotide competitor. Lanes 10–15, The ISRE–protein complex was
disrupted by antibodies to Stat-1 and Stat-2. Lanes 16–18, The ISRE–
protein complex was not disrupted by antibodies to IRF-1. A nonspecific
DNA–protein complex is shown at the bottom of each panel for refer-
ence (double arrow).
Figure 3. Nucleotide sequence of the HIV-1 LTR. C/EBP binding
sites determined by DNA footprinting are shown in boxes (from refer-
ence 19). The mutations introduced to abolish C/EBP binding are shown
below the wild-type sequence. The NF-kB sites are underlined. The
transcription start site is marked (arrow).
Figure 4. Time course of
HIV-1 LTR promoter activity in
stably transfected THP-1 cells.
(A) Wild-type HIV-1 LTR. M.
tuberculosis (d) or LPS (s) pro-
duces a striking decline in re-
porter activity in THP-1 mac-
rophages between 24 and 72 h.
(B) HIV-1 LTR with mutated
(mut) C/EBPb sites. M. tuberculo-
sis ( d ) or LPS (s) produces a
moderate increase in reporter ac-
tivity in THP-1 macrophages.1259 Honda et al.
with induction of inhibitory 16-kD C/EBPb. There was
.95% inhibition of transcription by IFN-b 72 h after
treatment. This was greater than the inhibition produced
by LPS stimulation or infection with M. tuberculosis (com-
pare Figs. 1 and 2 with Fig. 5 C).
C/EBPb Is the Predominant Transcription Factor Binding the
HIV-1 NRE in THP-1 Cell–derived Macrophages. EMSA
with an HIV-1 NRE probe was used to investigate which
C/EBP transcription factors bound to the HIV-1 LTR.
THP-1 macrophages stimulated with LPS increased NRE
binding 10-fold (Fig. 6 A, lanes 1 and 2). This binding is
specific to the C/EBP site of the NRE, since cold NRE
competed effectively with the DNA–protein complex (Fig.
6 A, lane 3), whereas an oligonucleotide with point muta-
tions in the C/EBP domain did not (Fig. 6 A, lane 4).
Over 95% of the C/EBP-specific NRE–protein complex
was supershifted with C/EBPb antibody (Fig. 6 A, lane 5).
The major NRE–protein complex observed with LPS
stimulation is also induced by infection of THP-1 mac-
rophages with M. tuberculosis (Fig. 6 B, lane 2, arrow). This
NRE–protein complex competed with cold wild-type
NRE oligonucleotide, but not C/EBP mutant oligonucle-
otide and supershifted with C/EBPb antibody (data not
shown). In these extracts, another rapidly migrating band
was observed (Fig. 6 B, double arrow). This band bound to
non-C/EBP sequences of the NRE, since EMSA using the
C/EBP-mutated NRE as a probe produced a single comi-
grating band (Fig. 6 B, lane 4). Wild-type or C/EBP-
mutated NRE probes by themselves did not produce these
bands (Fig. 6 B, lanes 1 and 3). The non-C/EBP NRE–
protein complex was heat labile, whereas the NRE–C/
EBPb complex reformed after heating extracts at 958C for
5 min (data not shown).
Inhibitory C/EBPb Is Strongly Expressed in Alveolar Mac-
rophages from Lung Segments with Low Viral Replication and Is
Downregulated in Inflamed Lung Segments with High Viral Rep-
lication. We investigated C/EBPb expression in the lung
to test if cells that suppress HIV-1 replication in vivo also
express the inhibitory 16-kD C/EBPb. The C/EBPb im-
munoblot pattern of BAL cells from a normal control (Fig.
7 A, lane 1) was similar to the pattern in macrophages stim-
ulated with LPS. Expression of the 16-kD C/EBPb was
striking. The ratio of inhibitory to stimulatory C/EBPb
was 1.8 (Table 1). To define which cell population ex-
pressed the C/EBPb, adherence was used to separate mac-
rophages from lymphocytes in the BAL. This procedure
works well in BAL cells from uninvolved lung; adherent
cells were 90–95% alveolar macrophages by morphology
and nonspecific esterase staining. The nonadherent cells
were 80–90% lymphocytes by morphology. Protein ex-
tracts were made from adherent (AD) and nonadherent
(Non) BAL cells from an uninvolved lobe of an AIDS pa-
tient with pulmonary tuberculosis. The adherent fraction
expressed at least sixfold more 16-kD C/EBPb (Fig. 7 A,
lanes 2 and 3), demonstrating that the 16-kD C/EBPb is
strongly expressed in the alveolar macrophages.
Figure 5. C/EBPb expression
and HIV-1 LTR reporter activ-
ity of THP-1 macrophages after
LPS or IFN-b stimulation. (A)
LPS induces inhibitory 16-kD
C/EBPb in the nuclear extracts
between 48 and 72 h. (B) Inhibi-
tory 16-kD C/EBPb is increased
3 h after IFN treatment of differ-
entiated THP-1 cells and is max-
imally induced after 48 h. The
level of inhibitory C/EBPb pro-
duced by LPS stimulation is the
same as that produced by IFN-b.
(C) The HIV-1 LTR is repressed
after 1 U/ml IFN-b in differen-
tiated BF-24 cells. There is a
50% decline in LTR activity af-
ter 3 h and a 95% decline in
LTR activity at 72 h.
Table 1. Densitometry of C/EBPb Immunoblot
THP-1 macrophages
Normal
BAL
Uninvolved
BAL 1LPS 1IFN-b
n 5 5n  5  4n  5  2n  5  6
Ratio
16-kD C/EBPb/ 0.8 6 0.64 3.6 6 2.4 1.8 6 0.9 1.0 6 0.8
37-kD C/EBPb
Figure 6. C/EBPb binding to the
HIV-1 LTR NRE in THP-1 macro-
phages. (A) Cells predominantly express
C/EBPb after LPS stimulation. Lane 1,
Unstimulated THP-1 cells with wild-
type NRE probe. Lane 2, Wild-type
NRE binding is increased 10-fold after
stimulation with PMA and LPS. Lane 3,
Competition with 100-fold excess unla-
beled wild-type NRE probe disrupts the
NRE–protein complex. Lane 4, 100-
fold excess unlabeled NRE mutated in
the C/EBP site does not disrupt the NRE–protein complex. Lane 5,
Antibody to C/EBPb supershifts .95% of the NRE–protein complex.
(B) THP-1 macrophages infected with M. tuberculosis (M. tb.) express
C/EBP-specific and C/EBP-nonspecific NRE–protein complexes. Lane 1,
Wild-type NRE probe only. Lane 2, Wild-type NRE binding in THP-1
macrophage extracts after M. tuberculosis infection produces a band similar
to LPS stimulation (arrow) and another more rapidly migrating NRE–pro-
tein complex (double arrow). Lane 3, C/EBP mutant NRE probe only.
Lane 4, C/EBP-mutated NRE probe produces a single complex with the
same mobility as the rapidly migrating wild-type NRE–protein complex
(double arrow) with extracts of M. tuberculosis–infected THP-1 macrophages.1260 Interferon Induces an Inhibitory C/EBP Transcription Factor
BAL cells from radiographically uninvolved lung segments
of six patients with pulmonary tuberculosis were similar to
the immunoblots of the normal control (Fig. 7 A, lanes 2, 4,
6, 8, 10, and 12). The ratio of inhibitory to stimulatory C/
EBPb was 1.0 (Table 1). Lung segments involved with tuber-
culosis had expressed 14 6 13% the level of 16-kD inhibitory
C/EBPb observed in uninvolved segments (Fig. 7 A, lanes 5,
7, 9, 11, and 13). Immunocompetent patients had the same
expression pattern as AIDS patients. Expression of 16-kD C/
EBPb increased in the involved lung segment after antituber-
culous chemotherapy (Fig. 6 B, lanes 13 and 14).
Reprobing of the blots with antibody to NF-kB p65 Rel
A demonstrated that adherent and nonadherent fractions
had similar amounts of NF-kB (Fig. 7 B, lanes 1 and 2).
NF-kB was equally or more strongly expressed in the in-
volved lung segment than in the uninvolved lung segment
(Fig. 7 B, lanes 3–10). This demonstrated that changes in
C/EBPb expression were not due to nonspecific protein
degradation or unequal loading of samples.
The BAL cellular differentials are shown in Table 2.
These results are similar to larger series of BAL differentials
in tuberculosis patients and normal controls (29). The lung
segment involved with tuberculosis has increased percent-
ages of lymphocytes and neutrophils compared with unin-
volved lung segments or normal controls. Involved lung
segments have a bimodal distribution of inflammatory cells,
with three of the patients having ,2% neutrophils, while
the other patients had 34 6 21% neutrophils. The 1.5-fold
enrichment of alveolar macrophages in the uninvolved
lobes does not account for the 6.6-fold enrichment of total
C/EBPb observed in the uninvolved BAL (Table 3).
Pulmonary Tuberculosis Switches C/EBP Expression in BAL
Cells. BAL cell extracts from uninvolved lobes have the
same EMSA pattern as THP-1 macrophages infected with M.
tuberculosis (Fig. 8, lanes 1 and 2). The uninvolved lobe from
five patients with pulmonary tuberculosis strongly binds the
HIV-1 LTR NRE (Fig. 8, lanes 2, 10, 18, 20, and 22). This
binding is specific for the C/EBP site, since binding could be
competed away by excess wild-type oligonucleotide (Fig. 8,
lanes 3 and 11) but not by mutant NRE (Fig. 8, lanes 4 and
12). Over 90% of the NRE–protein complexes supershifted
with antibody to C/EBPb (Fig. 8, lanes 5 and 13). The non-
C/EBP NRE–protein (nonspecific) complex observed in
THP-1 macrophages infected with M. tuberculosis was also
observed in BAL cell extracts from uninvolved and involved
lung segments (Fig. 8, double arrow).
EMSA confirmed the immunoblot observations. Unin-
volved lung segments had a marked increase in NRE bind-
ing compared with involved lobes from the same patient
(in Fig. 8, compare lanes 2, 10, 18, 20, and 22 with lanes 6,
14, 19, 21, and 23). Supershift with antibody to C/EBPb
demonstrated 6.6-fold greater C/EBPb expression in the
uninvolved lung segment (Table 3). In contrast, expression
of the nonspecific complex was increased 1.1-fold in the
uninvolved lung segment (Table 3). This nonspecific band
is an internal standard for DNA binding activity in unin-
volved and involved BAL extracts. The similar level of ex-
pression of the nonspecific NRE–protein complex in ex-
tracts from different sources demonstrated that changes in
Figure 7. Transcription factor expression in BAL cells from a normal
control and six patients with pulmonary tuberculosis. (A) Inhibitory 16-
kD C/EBPb is strongly expressed in BAL cells from uninflamed lung and
is downregulated in pulmonary tuberculosis. Lane 1, The inhibitory 16-
kD C/EBPb is strongly expressed in a normal control (NL). Lane 2, Ad-
herent BAL cells (Ad) from an uninvolved lobe of an AIDS patient with
tuberculosis strongly express inhibitory 16-kD C/EBPb. Adherent BAL
cells are .95% alveolar macrophages. Lane 3, Nonadherent cells (Non)
which are 80–90% lymphocytes have little inhibitory 16-kD C/EBPb
expression. Lanes 2, 4, 6, 8, 10, and 12 show that the inhibitory 16-kD
C/EBPb is strongly expressed in uninvolved lobes (UN) of six patients
with tuberculosis. Four are HIV-1 infected and two are HIV-1 negative.
Lanes 5, 7, 9, 11, and 13 show that the inhibitory 16-kD C/EBPb is
markedly downregulated in the involved lobes (IN) of these tuberculosis
patients. Lane 14, There is an increase in 16-kD C/EBPb in the involved
lobe after 2 wk of antituberculous chemotherapy (IN/Rx). (B) NF-kB
expression in BAL cells. Lanes 1–10 are the same blots as in A, lanes 2–11.
Lanes 1 and 2, The level of NF-kB expression is similar in adherent (Ad)
and nonadherent (Non) cells. Lanes 3–10, There is equal or increased
NF-kB expression in the involved lobes (IN) compared with the unin-
volved lobes (UN).
Table 2. BAL Cellular Differential
Pulmonary tuberculosis
Normal Uninvolved Involved
%% %
Macrophages 91 6 1 80 6 16 52 6 17
Lymphocytes 9 6 1 17 6 15 27 6 18
Neutrophils 0 1 6 0.9 20 6 22
Table 3. Densitometry of BAL NRE–Protein Complexes
C/EBPb supershift Nonspecific band
Ratio
uninvolved/involved 6.6 6 3.7 1.1 6 0.31261 Honda et al.
C/EBPb expression were not due to protein degradation
in the involved segment or to unequal loading of samples.
A new rapidly migrating band was observed in extracts
of BAL cells from the involved segment of five patients
(Fig. 8, lanes 5–8, arrow, 14–17, 19, 21, and 24). The in-
duced NRE–protein complex is specific for the C/EBP
site, since binding could be competed by excess wild-type
oligonucleotide (Fig. 8, lanes 7 and 15) but not by mutant
NRE (Fig. 8, lanes 8 and 16). Full data are shown from
two patients, but similar results were obtained from all five.
The rapidly migrating C/EBP-specific band expressed in
involved lung segments was observed in patients with and
without neutrophil-predominant BAL differentials. In ad-
dition, it did not supershift with antibody to C/EBPb (Fig.
8, lanes 9 and 17) or with antibodies to C/EBPa, C/EBPd,
C/EBPe, or C/EBP-homologous protein (CHOP) (data
not shown). Adherence was used to separate macrophages
from other cells in the involved BAL. Both the C/EBP-
specific and C/EBP-nonspecific NRE binding activity
were enriched in the adherent cell fraction (Fig. 8, lanes 24
and 25). Another slowly migrating NRE–protein complex
was expressed in nonadherent BAL cells. This complex did
not supershift with C/EBPb antibodies (data not shown).
Discussion
M. tuberculosis and other opportunistic infections includ-
ing Pneumocystis carinii, cryptococcus, CMV, and bacterial
infections enhance HIV-1 replication in vivo (2, 3, 30–34).
We previously reported significantly increased HIV-1
RNA and p24 levels in radiographically involved lobes in
tuberculosis/HIV-1 coinfected patients compared with un-
involved lobes or HIV-1–infected patients with no lung
disease (2). We also demonstrated that M. tuberculosis stimu-
lated HIV-1 replication in vitro as measured by increased
p24 in cell supernatants of undifferentiated U937 and
THP-1 cells over 4 d (30). We correlated these increases
with transcriptional activation at the tandem NF-kB sites
and the C/EBP sites on the HIV-1 LTR using CAT re-
porter constructs (30). Studies with the promonocyte U937
and monocytic THP-1 cell lines have shown that LPS and
TNF-a also enhance HIV-1 replication through activation
of NF-kB (35–37). Surprisingly, when monocytes are dif-
ferentiated to macrophages, LPS or other proinflammatory
stimuli suppress HIV-1 replication (8, 9). Inhibition of viral
replication in macrophages after proinflammatory stimuli is
a type I IFN effect (11, 12). We now demonstrate a novel
mechanism of transcriptional control by type I IFNs that al-
ter expression of C/EBPb, producing a dominant negative
transcription factor and repressing the HIV-1 LTR. In
vivo, alveolar macrophages from uninflamed lung behave
like IFN-b–treated macrophages, expressing the inhibitory
16-kDa C/EBPb and inhibiting HIV-1 replication. This
may contribute to viral latency in the uninflamed lung.
We showed that M. tuberculosis suppressed HIV-1 repli-
cation, repressed LTR activity, and induced ISGF-3, a type
I IFN–specific transcription factor, in THP-1 macrophages.
Two separate strains of HIV-1 were suppressed, demon-
strating that the effect was not strain specific. The forma-
tion of a type I IFN–specific transcription factor complex is
early in the IFN signaling cascade, induced by receptor-
directed protein phosphorylation. Since type I IFN mediates
strong antiviral activity, it is likely that the reduction of vi-
ral replication after M. tuberculosis infection is an IFN effect.
The suppression of HIV-1 replication correlated with re-
pression of LTR activity, suggesting that transcriptional
downregulation is one mechanism of inhibition of viral
replication in this system. The HIV-1 LTR has an NRE
with three C/EBP sites located 59 to a tandem NF-kB site
(19, 38, 39). The NRE is the sequence that mediates HIV-1
LTR repression after an inflammatory stimulus (8).
Productive infection of macrophages by HIV-1 occurs
predominantly in alveolar macrophages and macrophage-
lineage cells, e.g., in the brain, although monocyte-derived
macrophages are highly susceptible (6, 30, 40, 41). Differ-
entiated monocytic U1 cells suppress HIV-1 expression af-
ter treatment with IFN-g, IL-6, or GM-CSF (42). These
cytokines act transcriptionally on the stably integrated
HIV-1 LTR in U1 cells. Macrophage differentiation up-
regulates NF-IL6 (C/EBPb), and NF-IL6 is responsible for
regulating gene expression in mature macrophages (43). M.
tuberculosis stimulates production of macrophage cytokines IL-
1b, IL-6, and TNF-a, and C/EBP binding sites are in-
volved in the transcriptional regulation of these genes (44,
45). HIV-1 transcriptional regulation occurred independent
of NF-kB after U1 cells were treated with proinflamma-
Figure 8. C/EBPb binding to the HIV-1 LTR NRE in BAL cells from
six patients with pulmonary tuberculosis. Extracts from uninvolved lung
of patients with pulmonary tuberculosis predominantly express C/EBPb,
whereas BAL cells from involved lung downregulate C/EBPb and switch
expression to another C/EBP family member. Lane 1, NRE binding of
THP-1 macrophages infected with M. tuberculosis. Lanes 2–4, 10–13, 18,
20, and 22, NRE–protein complex in uninvolved lobes (UN) of HIV-
1–infected and HIV-1–negative patients with pulmonary tuberculosis. Lanes
2, 10, 18, 20, and 22, BAL cell extract strongly binds the NRE. A non-
specific band is also expressed in BAL extracts (double arrow). Lanes 3 and
11, 100-fold excess unlabeled NRE probe disrupts both the specific and
nonspecific complex. Lanes 4 and 12, 100-fold excess unlabeled mutant
probe does not affect the specific complex. Lanes 5 and 13, Anti-C/EBPb
antibody supershifts .90% of the complex. Lanes 6, 14, 19, 21, 23, and
24, Tuberculosis-involved lobes (IN) lose the predominant band expressed
in uninvolved lobes and switch expression to a faster migrating specific
NRE–protein complex (arrow). Lanes 7 and 15, 100-fold excess unlabeled
NRE disrupts the complex. Lanes 8 and 16, 100-fold excess unlabeled
mutant probe does not disrupt the complex. Lanes 9 and 17, Anti-C/EBPb
antibody does not supershift the complex. Lane 24, Adherent cells (Ad)
from an involved lobe strongly express specific and nonspecific NRE–
protein complexes. Lane 25, Nonadherent cells (Non) from the same in-
volved lobe have markedly reduced expression of the specific and non-
specific NRE–protein complexes.1262 Interferon Induces an Inhibitory C/EBP Transcription Factor
tory cytokines (39). Positive regulation can also occur
through interactions of C/EBP transcription factors with
the adjacent NF-kB (30). C/EBPb–NF-kB heterodimers
are more potent activators of the HIV-1 LTR than p50–
p65 complexes (46, 47). HIV-1 replication requires intact
C/EBP sites in monocytes but not lymphocytes, demon-
strating a requirement for C/EBP activators by HIV-1 only
in monocytes and macrophages (24). Thus, we evaluated
the C/EBP family of transcription factors to clarify the
mechanism of activation and suppression of the HIV-1
LTR in differentiated and activated macrophages.
Point mutations in the C/EBP sites of the HIV-1 LTR
NRE abolished promoter repression after stimulation with
LPS or infection with M. tuberculosis. The continued increase
in C/EBP-mutated HIV-1 LTR reporter activity over the
course of the experiments demonstrates that these macro-
phages could sustain high levels of transcription after inflam-
matory stimuli. Therefore, the decline in the wild-type HIV-1
LTR after M. tuberculosis or LPS was not due to a nonspecific
toxicity produced by the inflammatory stimuli. These results
were obtained with stably integrated LTR CAT and LTR
luciferase reporter constructs, demonstrating that the level of
stimulation is not critically dependent on the site of integration
or the reporter used. Repression of the wild-type HIV-1 LTR
was caused by a specific interaction of a transcriptional re-
pressor(s) with the C/EBP sites in the HIV-1 LTR.
Descombes and Schibler described two rat C/EBPb pro-
teins which either activated the albumin promoter (liver-acti-
vating protein [LAP]) or repressed the albumin promoter
(liver-enriched inhibitory protein [LIP]) (20). Both were
transcribed from the same mRNA by using in-frame AUGs.
Both proteins share the 145 COOH-terminal amino acids
that contain the basic DNA-binding domain and the leucine
zipper dimerization helix. LAP uses the first and second AUG
start site and LIP the third, resulting in only LAP having
the  transcriptional activation domain (20). Consequently,
LAP is a longer protein (z39 kD) than LIP (z16 kD). How-
ever, LIP has higher binding affinity for its DNA cognate se-
quences, resulting in its ability to attenuate the transcriptional
stimulation of LAP in substoichiometric amounts. Small
changes in the LIP to LAP ratio resulted in large differences
in transcription, with promoter repression occurring at ratios
.0.2 (20, 21). LIP is also induced in mouse liver by LPS
(48). Our data suggest that Kupffer cells may contribute to
the increase in LIP observed in the liver after LPS treatment.
In vitro, expression of the inhibitory 16-kD C/EBPb re-
presses promoters containing C/EBP sites in monocytes and
macrophages. When the 16-kD C/EBPb is cotransfected
with the HIV-1 LTR, transcription is strongly inhibited
(22), and cell lines with engineered expression of the
C/EBPb dominant negative isoform suppress induction of
provirus and HIV-1 replication (23). Cytokine genes such
as TNF-a also have C/EBP binding sites, and transfection
of inhibitory C/EBPb represses TNF-a promoter activity
(26). The relevance of these in vitro studies is undefined,
since endogenous expression of inhibitory 16-kD C/EBPb
in monocytes and macrophages has not been studied.
We demonstrate here that macrophages induce a domi-
nant negative 16-kD C/EBPb transcription factor after stim-
ulation with LPS or infection with M. tuberculosis. C/EBPb
is the predominant C/EBP family member in these cells.
EMSA demonstrates that C/EBPb is in .95% of NRE–
protein complexes induced by these inflammatory stimuli.
The induction of this transcriptional repressor in our model
is coincident with repression of the HIV-1 LTR. Both stim-
ulatory and inhibitory C/EBPb isoforms are expressed, but
repression would be expected because the 16-kD C/EBPb
is dominant negative, inhibiting transcription when ex-
pressed at 20% the level of the 37-kD isoform (20, 21). All
cells that inhibited HIV-1 replication or LTR promoter
function had a higher ratio of inhibitory to stimulatory iso-
forms (Table 1). Since C/EBPb is the predominant tran-
scription factor induced by inflammatory stimuli and intact
C/EBP sites are required for LTR repression, induction of
endogenous inhibitory 16-kD C/EBPb is most likely
responsible for LTR repression after inflammatory stimula-
tion. This conclusion is strongly supported by the obser-
vation that engineered expression of 16-kD C/EBPb
represses the LTR and inhibits HIV-1 replication (22, 23).
Treatment of macrophages with IFN-b induces a domi-
nant negative C/EBPb transcription factor and represses
HIV-1 LTR promoter within 3 h. Given the rapid effect of
IFN-b on 16-kD C/EBPb induction and LTR repression,
it is likely that these are direct IFN effects. These effects
occur at low doses. 1 U/ml of IFN-b maximally induces
inhibitory C/EBPb and maximally represses the HIV-1
LTR. Therefore, one mechanism of inhibition of viral rep-
lication by type I IFN is transcriptional repression. The ra-
tio of inhibitory to stimulatory C/EBPb is 3.6 after treat-
ment with IFN-b compared with a ratio of 0.8 after
treatment with LPS. This may account for the greater LTR
repression produced by IFN-b. Taken together with the
induction of ISGF-3 by M. tuberculosis, these data suggest
that M. tuberculosis and LPS repress the LTR by producing
an IFN response in macrophages.
Induction of a dominant negative C/EBPb transcription
factor by type I IFN reveals a highly unusual form of regu-
lation. The C/EBPb gene has no introns, so the change in
coding potential of the mRNA is regulated by a ribosome
scanning mechanism (20, 48). After IFN-b stimulation,
the ribosome selects an internal ribosome entry site in the
C/EBPb mRNA, producing dominant negative transcrip-
tion factors 16–20-kD in size. In the absence of IFN stimu-
lation, the ribosome selects the 59 translation start sites,
producing stimulatory transcription factors 35–37-kD in
size. IFN stimulation can produce a rapid switch from tran-
scriptional stimulation to transcriptional repression without
changes in levels of C/EBPb mRNA. It is possible that
phosphorylation of translation initiation factors by double-
stranded protein kinase alters ribosome function, producing
altered translation start site usage. IFN-b–treated macro-
phages are the first in vitro system to regulate inhibitory
C/EBPb production, and this model will be useful to inves-
tigate translation start site switching in the C/EBPb mRNA.
Alveolar macrophages from normal lung are primed by
type I IFN even in the absence of viral infection (13). Ex-1263 Honda et al.
pression of innate immunity in the uninflamed lung may
contribute to viral latency. In vivo, resting alveolar mac-
rophages from AIDS patients with no detectable viral repli-
cation strongly express the inhibitory 16-kD C/EBPb. The
ratio of inhibitory to stimulatory C/EBPb is 1.0 in these
lung segments. The inhibition of viral replication in unin-
flamed lung is similar to IFN-b–treated macrophages in
vitro (9). Therefore, IFN-treated macrophages are a good
model for resting alveolar macrophages. AIDS does not al-
ter regulation of C/EBPb, since the ratio of inhibitory to
stimulatory C/EBPb is similar in HIV-1–infected and
HIV-1–negative patients. HIV-1 latency in alveolar mac-
rophages in uninflamed lung is encouraged by increased
expression of this C/EBPb 16-kD inhibitory isoform, and
our in vitro experiments with differentiated and stimulated
macrophages support this novel concept.
Our data demonstrate that M. tuberculosis infection in
vivo suppresses C/EBPb proteins, particularly the 16-kD
inhibitory isoform. There is 6.6-fold greater C/EBPb–
mediated NRE binding in the uninvolved lobes than in the
involved lobes (Table 3). NF-kB expression is equal or
higher in the involved segment on the immunoblot. Fur-
thermore, nonspecific NRE binding activity is similar in
uninvolved and involved lung segments (only 1.1-fold in-
creased) in EMSA from five patients. Therefore, it is un-
likely that the diminished C/EBPb expression in involved
lobes is due to nonspecific protein degradation. We pro-
pose that loss of the inhibitory C/EBPb expression ob-
served in pulmonary tuberculosis derepresses the HIV-1
LTR. Derepression may be one mechanism for enhanced
HIV-1 replication observed in pulmonary tuberculosis.
A C/EBP DNA binding protein is induced in BAL cells
during pulmonary tuberculosis. This NRE–protein com-
plex is not supershifted by antibodies to C/EBPa, C/EBPb,
C/EBPd, C/EBPe, or CHOP, raising the possibility that
the NRE binding protein is a novel member of the C/EBP
transcription factor family. This NRE binding activity is
enriched in adherent BAL cells, suggesting that it is ex-
pressed in alveolar macrophages. Since C/EBP binding
sites of the LTR are required for HIV-1 replication in
macrophages (24), it is possible that the novel C/EBP
binding protein is important in the high level of replication
observed in pulmonary tuberculosis (2, 6). This transcrip-
tion factor is a candidate to stimulate C/EBP-containing
promoters during pulmonary tuberculosis and possibly
other diseases associated with macrophage activation. Fur-
ther experiments defining the modulation of these nuclear
proteins may improve the understanding of HIV-1 latency
in tissue macrophages and provide novel approaches to
pursuing elimination of this clever pathogen.
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